A Multi-center, Open-label Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-Related Macular Degeneration
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Sevacizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Jiangsu T-mab BioPharma
- 27 Feb 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
- 03 Sep 2017 Status changed from not yet recruiting to recruiting.
- 19 Jan 2017 New trial record